Coherus Biosciences (CHRS) PT Lowered to $27 at Truist Securities
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Amazon.com warehouse workers vote to reject forming union in Alabama
Truist Securities lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $27.00 (from $30.00) while maintaining a Buy rating.
You May Also Be Interested In
- FinecoBank (FBK:IM) PT Raised to EUR15.60 at Goldman Sachs
- Enerplus Corp. (ERF:CN) (ERF) PT Raised to Cdn$10 at TD Securities
- Enerplus Corp. (ERF:CN) (ERF) PT Raised to Cdn$7.50 at Scotiabank
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!